You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Portable Liquid Chromatograph for Point-of-Care Monitoring of Illicit Substances

    SBC: AXCEND LLC            Topic: R41

    Project Summary Abstract Point of carePOCtesting of clinical samples for the presence of illegal substances and their metabolites is important for monitoring substance use disordersemployment screeningand legal matters relating to drug abstinenceTypical immunoassay screening methods suffer from higher false testing rates and do not provide quantitative informationConfirmatory tests that are used f ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Point of care detection of extracellular vesicles in urine for diagnosis of preeclampsia

    SBC: Sersense Inc            Topic: NICHD

    PreeclampsiaPEis a pregnancy specific disorder characterized by hypertension and commonly by the appearance of urinary proteinThis disorder occurs inof pregnancies worldwide and is the second leading cause of maternal fetal morbidity and mortality worldwideIn low resource settingsPE accounts for up toof maternal deathsThe etiology of this disease is poorly understoodThis confounds therapeutic inte ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Optimizing Direct Delivery of Nucleic Acid Therapeutics

    SBC: FHC, INC.            Topic: NIMH

    Project Summary While nucleic acid therapeutics have shown promise in rodent and nonhuman primate models of CNS diseasesall double blind clinical trials to date have failedOne likely explanation for this failure is poor therapeutic distribution in targeted brain regionsFor examplepost mortem studies of patients with Parkinsonandapos s Disease receiving intraparenchymal injections of AAV NTN demons ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. O-Glycan-dependent Immunotherapy for Cancer

    SBC: GlyTR Therapeutics, Inc.            Topic: 102

    Abstract For decadesthe treatment of cancer has relied on surgical resectionchemotherapy and or radiotherapyRecentlya number of immune based therapies have provided promising new approaches for cancer treatmentThe two most potent immunotherapies are monoclonal antibodymABbased bi specific proteinseg Bispecific T cell engagersBiTEand engineered Chimeric Antigen Receptor T cellsCAR TBoth act by indu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Treatment for Degenerative Myopia

    SBC: VISDEX CORP            Topic: N/A

    DESCRIPTION (provided by applicant): Photopolymerization has provided a powerful tool for tissue engineering through localized synthesis of therapeutic materials in situ. To date, strategies to create photopolymerized networks on the surface of a tissue, such as the inner lumen of a blood vessel or on the fracture surface of a bone have received the most attention. The proposal will demonstrate a ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Stroke

    SBC: BioTime, Inc.            Topic: 100

    ABSTRACT Stroke is a leading cause of disability worldwideGloballythere aremillion stroke survivors each year who have significant neurological deficits including sensory and motor disabilityleading to excessive socioeconomic burdenCell therapy using primary MSCs has been actively explored by us and others as a therapeutic solution to this unmet medical needHoweversince the therapeutic efficacy of ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. New Opioids for Alcoholism

    SBC: BEHAVIORAL PHARMA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  8. Newborn Screening for Sex Chromosome Disorders

    SBC: JS GENETICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Turner syndrome (TS) is the most common genetic problem effecting women, with an incidence of 1 in 1,500 to 2,000 live female births and occurs when an entire, or portions of an X-chromosome is deleted. Phenotypic features include primary hypogonadism, renal abnormalities, and profound short stature. Yet, with growth hormone therapy, acceptable adult stature c ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  9. New APEX diagnostic for hereditary sensorineural hearing loss

    SBC: APEX DX, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): In developed countries, approximately 1:1000 children are born deaf and approximately 1:300 children are born with some lesser degree of hearing loss. At least 50% of the deafness and hearing impairment is likely to be attributable to genetic factors, with a large number of genes involved in the pathogenesis. The molecular genetic basis for the majority of case ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  10. NANOTEMPLATE ENGINEERING OF A STEALTH MRI CONTRAST AGENT

    SBC: NANOMED PHARMACEUTICALS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The increasing costs of therapy and the demonstrated benefits of improved treatment efficacy with early detection are important incentives to develop tumor diagnostic agents of greater specificity and sensitivity. Paramagnetic gadolinium complexes are widely used as MRI (magnetic resonance imaging) contrast agents to improve sensitivity and/or specificity duri ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government